Nektar Therapeutics (NKTR) Stock Forecast, Price Target & Predictions
NKTR Stock Forecast
Nektar Therapeutics stock forecast is as follows: an average price target of $16.75 (represents a 1760.08% upside from NKTR’s last price of $0.90) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NKTR Price Target
NKTR Analyst Ratings
Buy
Nektar Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 18, 2022 | Mara Goldstein | Mizuho Securities | $6.00 | $4.74 | 26.58% | 566.30% |
Mar 01, 2022 | Jessica Fye | J.P. Morgan | $17.00 | $10.98 | 54.83% | 1787.84% |
Nov 08, 2021 | Aydin Huseynov | Ladenburg Thalmann & Co. | $20.00 | $14.65 | 36.52% | 2120.99% |
May 18, 2021 | Chris Shibutani | Goldman Sachs | $24.00 | $18.13 | 32.38% | 2565.19% |
Nektar Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.90 | $0.90 | $0.90 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 04, 2024 | Piper Sandler | Overweight | Initialise | |
Jun 28, 2024 | Rodman & Renshaw | Buy | Initialise | |
Nov 09, 2023 | Cowen & Co. | Outperform | Upgrade | |
May 10, 2023 | Jefferies | Hold | Upgrade | |
Mar 06, 2023 | Oppenheimer | Perform | Perform | Hold |
Nektar Therapeutics Financial Forecast
Nektar Therapeutics Revenue Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $24.14M | $20.50M | $21.59M | $22.02M | $23.63M | $21.59M | $24.82M | $25.01M | $24.92M | $28.33M | $23.65M | $23.46M | $30.03M |
Avg Forecast | $17.00M | $17.00M | $17.00M | $17.00M | $25.09M | $24.72M | $24.36M | $24.15M | $22.77M | $21.66M | $21.50M | $20.85M | $36.60M | $19.18M | $18.20M | $15.34M | $21.43M | $21.26M | $21.79M | $19.41M | $22.14M | $22.61M | $22.62M | $24.30M | $34.26M | $28.13M | $26.15M | $25.73M | $29.86M | $22.59M |
High Forecast | $31.28M | $31.28M | $31.28M | $31.28M | $46.17M | $45.49M | $44.83M | $44.44M | $41.90M | $39.85M | $39.56M | $33.23M | $81.34M | $20.18M | $33.50M | $15.34M | $29.05M | $21.26M | $40.10M | $35.72M | $40.74M | $22.61M | $22.62M | $24.30M | $34.26M | $28.13M | $26.15M | $25.73M | $29.86M | $22.59M |
Low Forecast | $9.64M | $9.64M | $9.64M | $9.64M | $14.23M | $14.02M | $13.82M | $13.70M | $12.92M | $12.29M | $12.20M | $14.84M | $21.54M | $18.17M | $10.33M | $15.34M | $6.39M | $21.26M | $12.36M | $11.01M | $12.56M | $22.61M | $22.62M | $24.30M | $34.26M | $28.13M | $26.15M | $25.73M | $29.86M | $22.59M |
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 10 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 0.94% | 1.11% | 0.99% | 1.04% | 0.95% | 1.02% | 0.73% | 0.89% | 1.08% | 0.92% | 0.79% | 1.33% |
Forecast
Nektar Therapeutics EBITDA Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 10 |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-44.86M | $-50.60M | $-32.98M | $-37.76M | $-32.74M | $-45.70M | $-110.96M | $-134.09M | $-113.17M | $-108.53M | $-106.04M | $-105.65M | $-96.89M |
Avg Forecast | $-17.00M | $-17.00M | $-17.00M | $-17.00M | $-25.09M | $-24.72M | $-24.36M | $-24.15M | $-22.77M | $-21.66M | $-21.50M | $-20.85M | $-36.60M | $-19.18M | $-18.20M | $-122.31M | $-21.43M | $-21.26M | $-21.79M | $-111.19M | $-151.14M | $-22.61M | $-22.62M | $-101.08M | $-34.26M | $-28.13M | $-26.15M | $-111.93M | $-29.86M | $-22.59M |
High Forecast | $-9.64M | $-9.64M | $-9.64M | $-9.64M | $-14.23M | $-14.02M | $-13.82M | $-13.70M | $-12.92M | $-12.29M | $-12.20M | $-14.84M | $-21.54M | $-18.17M | $-10.33M | $-97.85M | $-6.39M | $-21.26M | $-12.36M | $-88.95M | $-120.91M | $-22.61M | $-22.62M | $-80.87M | $-34.26M | $-28.13M | $-26.15M | $-89.54M | $-29.86M | $-22.59M |
Low Forecast | $-31.28M | $-31.28M | $-31.28M | $-31.28M | $-46.17M | $-45.49M | $-44.83M | $-44.44M | $-41.90M | $-39.85M | $-39.56M | $-33.23M | $-81.34M | $-20.18M | $-33.50M | $-146.77M | $-29.05M | $-21.26M | $-40.10M | $-133.43M | $-181.36M | $-22.61M | $-22.62M | $-121.30M | $-34.26M | $-28.13M | $-26.15M | $-134.31M | $-29.86M | $-22.59M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.11% | 2.32% | 0.30% | 0.25% | 1.45% | 2.02% | 1.10% | 3.91% | 4.02% | 4.15% | 0.95% | 3.54% | 4.29% |
Forecast
Nektar Therapeutics Net Income Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 10 |
Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-45.84M | $-51.12M | $-137.02M | $-59.69M | $-59.05M | $-159.07M | $-90.39M | $-145.65M | $-129.71M | $-125.52M | $-122.97M | $-117.20M | $-108.59M |
Avg Forecast | $-44.99M | $-45.43M | $-45.89M | $-46.75M | $-48.43M | $-48.66M | $-47.38M | $-45.73M | $-39.61M | $-39.95M | $-38.71M | $-40.66M | $-26.73M | $-41.64M | $-38.71M | $-139.94M | $-44.03M | $-41.50M | $-58.90M | $-127.21M | $-164.17M | $-93.76M | $-202.56M | $-115.65M | $-167.76M | $-166.65M | $-152.62M | $-129.80M | $-142.06M | $-157.74M |
High Forecast | $-19.68M | $-19.88M | $-20.08M | $-20.45M | $-21.19M | $-21.29M | $-20.73M | $-20.01M | $-17.33M | $-17.48M | $-16.94M | $-34.24M | $31.58M | $-18.22M | $-16.94M | $-111.95M | $-35.23M | $-18.16M | $-25.77M | $-101.77M | $-131.33M | $-93.76M | $-202.56M | $-92.52M | $-167.76M | $-166.65M | $-152.62M | $-103.84M | $-142.06M | $-157.74M |
Low Forecast | $-94.13M | $-95.05M | $-96.01M | $-97.80M | $-101.33M | $-101.81M | $-99.14M | $-95.68M | $-82.88M | $-83.58M | $-80.99M | $-49.22M | $-43.73M | $-87.13M | $-80.99M | $-167.92M | $-50.64M | $-86.82M | $-123.23M | $-152.66M | $-197.00M | $-93.76M | $-202.56M | $-138.78M | $-167.76M | $-166.65M | $-152.62M | $-155.76M | $-142.06M | $-157.74M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 0.87% | 1.08% | 0.36% | 0.63% | 0.79% | 0.78% | 0.87% | 0.78% | 0.82% | 0.95% | 0.83% | 0.69% |
Forecast
Nektar Therapeutics SG&A Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 10 |
SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $21.15M | $17.87M | $21.08M | $21.94M | $22.53M | $20.52M | $27.34M | $32.14M | $29.47M | $29.55M | $31.68M | $27.14M | $26.98M |
Avg Forecast | $15.69M | $15.69M | $15.69M | $15.69M | $23.15M | $22.81M | $22.48M | $22.28M | $21.01M | $19.98M | $19.83M | $19.23M | $33.77M | $17.69M | $16.80M | $14.16M | $19.77M | $19.62M | $20.10M | $17.91M | $20.42M | $20.97M | $20.98M | $22.54M | $31.78M | $26.10M | $24.26M | $23.86M | $27.69M | $20.95M |
High Forecast | $28.86M | $28.86M | $28.86M | $28.86M | $42.60M | $41.97M | $41.36M | $41.01M | $38.66M | $36.77M | $36.50M | $30.66M | $75.05M | $18.62M | $30.91M | $14.16M | $26.80M | $19.62M | $37.00M | $32.96M | $37.58M | $20.97M | $20.98M | $22.54M | $31.78M | $26.10M | $24.26M | $23.86M | $27.69M | $20.95M |
Low Forecast | $8.90M | $8.90M | $8.90M | $8.90M | $13.13M | $12.94M | $12.75M | $12.64M | $11.92M | $11.34M | $11.25M | $13.69M | $19.88M | $16.77M | $9.53M | $14.16M | $5.90M | $19.62M | $11.41M | $10.16M | $11.59M | $20.97M | $20.98M | $22.54M | $31.78M | $26.10M | $24.26M | $23.86M | $27.69M | $20.95M |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 0.89% | 1.18% | 1.07% | 1.07% | 0.98% | 1.21% | 1.01% | 1.13% | 1.22% | 1.33% | 0.98% | 1.29% |
Forecast
Nektar Therapeutics EPS Forecast
Quarter
Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 10 | 10 |
EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | $-0.85 | $-0.49 | $-0.79 | $-0.70 | $-0.69 | $-0.68 | $-0.65 | $-0.61 |
Avg Forecast | $-0.21 | $-0.22 | $-0.22 | $-0.22 | $-0.23 | $-0.23 | $-0.23 | $-0.22 | $-0.19 | $-0.19 | $-0.18 | $-0.19 | $-0.13 | $-0.20 | $-0.18 | $-0.19 | $-0.21 | $-0.20 | $-0.28 | $-0.25 | $-0.45 | $-0.45 | $-0.97 | $-0.63 | $-0.80 | $-0.80 | $-0.73 | $-0.73 | $-0.68 | $-0.76 |
High Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.10 | $-0.08 | $-0.08 | $-0.08 | $-0.16 | $0.15 | $-0.09 | $-0.08 | $-0.08 | $-0.17 | $-0.09 | $-0.12 | $-0.11 | $-0.20 | $-0.45 | $-0.97 | $-0.63 | $-0.80 | $-0.80 | $-0.73 | $-0.73 | $-0.68 | $-0.76 |
Low Forecast | $-0.45 | $-0.45 | $-0.46 | $-0.47 | $-0.48 | $-0.49 | $-0.47 | $-0.46 | $-0.40 | $-0.40 | $-0.39 | $-0.24 | $-0.21 | $-0.42 | $-0.39 | $-0.40 | $-0.24 | $-0.41 | $-0.59 | $-0.52 | $-0.95 | $-0.45 | $-0.97 | $-0.63 | $-0.80 | $-0.80 | $-0.73 | $-0.73 | $-0.68 | $-0.76 |
Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21% | 0.96% | 2.94% | 0.71% | 0.69% | 0.88% | 0.78% | 0.98% | 0.88% | 0.94% | 0.93% | 0.96% | 0.81% |
Forecast
Nektar Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
NKTR | Nektar Therapeutics | $1.02 | $16.75 | 1542.16% | Buy |
SPRO | Spero Therapeutics | $1.04 | $10.00 | 861.54% | Buy |
TIL | Instil Bio | $21.69 | $150.00 | 591.56% | Hold |
NXTC | NextCure | $0.90 | $3.00 | 233.33% | Buy |
CTMX | CytomX Therapeutics | $1.13 | $3.47 | 207.08% | Buy |
NUVB | Nuvation Bio | $2.81 | $7.00 | 149.11% | Buy |
ASMB | Assembly Biosciences | $14.28 | $35.50 | 148.60% | Buy |
ACHL | Achilles Therapeutics | $0.97 | $2.00 | 106.19% | Buy |